WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc.(ALNY), an RNAi therapeutics company, on Thursday reported a net income for the first quarter of fiscal 2026, supported by a surge in revenue, driven by net product revenues.
Yvonne Greenstreet, CEO of Alnylam, said: '2026 is off to a strong start for Alnylam with the end of the first quarter marking one year since the U.S. launch of AMVUTTRA for ATTR-CM, and also representing a significant financial milestone with the achievement of over $1 billion in quarterly product revenues for the first time in our history.'
For the three-month period to March 31, the drugmaker reported a net income of $205.991 million, compared with a net loss of $18.251 million in the same period last year. Net profit per share stood at $1.51 as against a net loss of $0.14 per share a year ago. Excluding items, earnings were $273.038 million, or $1.99 per share, compared with $37.941 billion, or $0.29 per share, last year.
Income from operations surged to $268.636 million from $18.077 million in the previous year.
Total revenue was $1.167 billion, up from $594.189 million in the previous year. Net product revenues jumped to $1.036 billion from $468.538 million last year. Revenue from AMVUTTRA was $889.931 million, higher than $309.992 million a year ago.
Looking ahead for fiscal 2026, Alnylam has reaffirmed total net product revenue guidance of $4.900 billion to $5.300 billion, up 64% to 77% from last year.
ALNY was up by 8.57% at $327 in the pre-market trade on the Nasdaq.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
